Sihuan's Meiyan Space takes strategic stake in collagen maker Hanteng Bio

What's the deal? Sihuan PharmaceuticalDealroom has a profile for this one. Try Dealroom → (00460.HK) said its subsidiary Meiyan Space Biotechnology (Jilin) has completed a strategic equity investment in Guangzhou Hanteng BiotechnologyDealroom has a profile for this one. Try Dealroom →, a maker of recombinant human collagen raw material. The two firms also plan a joint commercialisation partnership.

What's the endgame? The partnership centres on Hanteng's full-length triple-helix recombinant human collagen raw material. Meiyan Space will use the material to develop a line of collagen-based aesthetic medicine products.

Why now? The deal, announced in October 2026, is designed to round out Sihuan's regenerative aesthetic medicine business. Securing an upstream collagen supplier gives Meiyan Space control over a key input for its product pipeline.

The signal: By moving into raw-material supply, Sihuan is building a more vertically integrated position in China's regenerative aesthetics market — owning both the ingredient and the finished products it feeds.

Read more: sohu.com

Image credit: Generated with Gemini